Regenerative Medicine Market by Product (Stem Cell, Immunotherapy, Gene Therapy, Tissue Engineering), Application (Musculoskeletal, Cancer, Dermatology, CVD, Ophthalmology, Neurology), Region, Competition - Global Forecast to 2031

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 STUDY SCOPE
  • 1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE
  • 1.3.2 INCLUSIONS & EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
  • 1.3.4 CURRENCY CONSIDERED
• 1.4 STAKEHOLDERS
• 1.5 SUMMARY OF CHANGES

2 EXECUTIVE SUMMARY

• 2.1 KEY INSIGHTS AND MARKET HIGHLIGHTS
• 2.2 KEY MARKET PARTICIPANTS: SHARE INSIGHTS AND STRATEGIC DEVELOPMENTS
• 2.3 DISRUPTIVE TRENDS SHAPING THE MARKET
• 2.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS
• 2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST

3 PREMIUM INSIGHTS

• 3.1 REGENERATIVE MEDICINE MARKET OVERVIEW
• 3.2 REGENERATIVE MEDICINE MARKET, BY TYPE & REGION
• 3.3 REGENERATIVE MEDICINE MARKET: GEOGRAPHIC SNAPSHOT
• 3.4 REGENERATIVE MEDICINE MARKET SHARE, BY PRODUCT 2026 VS 2031

4 MARKET OVERVIEW

• 4.1 INTRODUCTION
• 4.2 MARKET DYNAMICS
  • 4.2.1 DRIVERS
    • 4.2.1.1 Expanding clinical pipeline and increasing commercialization of regenerative therapies
    • 4.2.1.2 Broadening therapeutic applications of regenerative medicine
    • 4.2.1.3 Increased investment and strategic partnerships
    • 4.2.1.4 Advancing regulatory support for regenerative therapies
  • 4.2.2 RESTRAINTS
    • 4.2.2.1 High treatment costs and reimbursement constraints
    • 4.2.2.2 Long-term safety and durability uncertainties
  • 4.2.3 OPPORTUNITIES
    • 4.2.3.1 Allogeneic and iPSC-derived "off-the-shelf" cell therapies
    • 4.2.3.2 Clinical translation of tissue engineering and 3D bioprinting
  • 4.2.4 CHALLENGES
    • 4.2.4.1 Shortage of specialized manufacturing infrastructure and skilled personnel
• 4.3 UNMET NEEDS AND WHITE SPACES
• 4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES
• 4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS

5 INDUSTRY TRENDS

• 5.1 PORTER'S FIVE FORCES ANALYSIS
  • 5.1.1 THREAT OF NEW ENTRANTS
  • 5.1.2 THREAT OF SUBSTITUTES
  • 5.1.3 BARGAINING POWER OF BUYERS
  • 5.1.4 BARGAINING POWER OF SUPPLIERS
  • 5.1.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.2 MACROECONOMIC OUTLOOK
  • 5.2.1 INTRODUCTION
  • 5.2.2 GDP TRENDS AND FORECAST
  • 5.2.3 TRENDS IN GLOBAL REGENERATIVE MEDICINE MARKET
• 5.3 VALUE CHAIN ANALYSIS
• 5.4 ECOSYSTEM ANALYSIS
• 5.5 PRICING ANALYSIS
  • 5.5.1 AVERAGE SELLING PRICE TREND, BY KEY PLAYER (2023-2025)
  • 5.5.2 AVERAGE SELLING PRICE, BY REGION (2025)
• 5.6 KEY CONFERENCES & EVENTS
• 5.7 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
• 5.8 INVESTMENT/FUNDING ACTIVITY
• 5.9 CASE STUDY ANALYSIS
• 5.10 IMPACT OF 2025 US TARIFFS-REGENERATIVE MEDICINE MARKET
  • 5.10.1 INTRODUCTION
  • 5.10.2 KEY TARIFF RATES
  • 5.10.3 PRICE IMPACT ANALYSIS
  • 5.10.4 IMPACT ON COUNTRIES/REGIONS
    • 5.10.4.1 North America
    • 5.10.4.2 Europe
    • 5.10.4.3 Asia Pacific
  • 5.10.5 IMPACT ON END-USE INDUSTRIES
    • 5.10.5.1 Hospitals
    • 5.10.5.2 Specialty clinics and cancer centers
    • 5.10.5.3 Other specialty care settings

6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS

• 6.1 KEY EMERGING TECHNOLOGIES
  • 6.1.1 AI-DRIVEN CELL & GENE THERAPY DEVELOPMENT
  • 6.1.2 SMART BIOMATERIALS & INJECTABLE SCAFFOLDS
• 6.2 ADJACENT TECHNOLOGIES
  • 6.2.1 ORGANOID & ORGAN-ON-CHIP TECHNOLOGIES
  • 6.2.2 ADVANCED IMAGING & CELL CHARACTERIZATION TECHNOLOGIES
• 6.3 COMPLEMENTARY TECHNOLOGIES
  • 6.3.1 BIOREACTORS & ADVANCED CELL CULTURE SYSTEMS
  • 6.3.2 CELL EXPANSION & CELL PROCESSING TECHNOLOGIES
• 6.4 TECHNOLOGY/PRODUCT ROADMAP
• 6.5 PIPELINE ANALYSIS
• 6.6 FUTURE APPLICATIONS
• 6.7 IMPACT OF AI/GEN AI ON REGENERATIVE MEDICINE MARKET
  • 6.7.1 TOP USE CASES AND MARKET POTENTIAL
  • 6.7.2 CASE STUDIES OF AI IMPLEMENTATION IN REGENERATIVE MEDICINE MARKET
  • 6.7.3 INTERCONNECTED ADJACENT ECOSYSTEM AND IMPACT ON MARKET PLAYERS
  • 6.7.4 CLIENTS' READINESS TO ADOPT GENERATIVE AI IN REGENERATIVE MEDICINE MARKET

7 REGULATORY LANDSCAPE AND SUSTAINABILITY INITIATIVES

• 7.1 REGIONAL REGULATIONS AND COMPLIANCE
  • 7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 7.1.2 INDUSTRY STANDARDS
• 7.2 SUSTAINABILITY INITIATIVES
• 7.3 IMPACT OF REGULATORY POLICIES ON SUSTAINABILITY INITIATIVES
• 7.4 CERTIFICATIONS, LABELING, & ECO-STANDARDS

8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR

• 8.1 DECISION-MAKING PROCESS
• 8.2 BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA
  • 8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 8.2.2 KEY BUYING CRITERIA FOR REGENERATIVE MEDICINE PRODUCTS, BY END USER
• 8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES
• 8.4 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES
• 8.5 MARKET PROFITABILITY

9 REGENERATIVE MEDICINE MARKET, BY PRODUCT

• 9.1 INTRODUCTION
• 9.2 CELL THERAPY
  • 9.2.1 STEM CELL THERAPY
    • 9.2.1.1 Cell transplantations
      • 9.2.1.1.1 Potential of Allo-SCT in treating AML to drive segmental growth
    • 9.2.1.2 Stem cell therapy products
      • 9.2.1.2.1 Autologous therapy
        • 9.2.1.2.1.1 Low risk of post-treatment complications to support segment growth
      • 9.2.1.2.2 Allogeneic therapy
        • 9.2.1.2.2.1 High potential in disease treatment to ensure demand and development
  • 9.2.2 CELL-BASED IMMUNOTHERAPY
    • 9.2.2.1 Growing adoption of T-cell therapy in cancer treatment to support market growth
• 9.3 GENE THERAPY
  • 9.3.1 STRONG PRODUCT PIPELINE DUE TO BROADENING APPLICATIONS IN DISEASE TREATMENT TO DRIVE MARKET
• 9.4 TISSUE ENGINEERING
  • 9.4.1 HIGH DEMAND FOR TISSUE ENGINEERING PRODUCTS IN DERMATOLOGY & WOUND CARE APPLICATIONS TO DRIVE MARKET

10 REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA

• 10.1 INTRODUCTION
• 10.2 ONCOLOGY
  • 10.2.1 INCREASING STEM CELL TRANSPLANTS TO DRIVE MARKET
• 10.3 MUSCULOSKELETAL DISORDERS
  • 10.3.1 RISING RESEARCH ON MUSCULOSKELETAL REGENERATION AND PREVALENCE OF ORTHOPEDIC DISORDERS TO DRIVE MARKET
• 10.4 DERMATOLOGY & WOUND CARE
  • 10.4.1 RISING USE OF WOUND CARE BIOLOGICS TO DRIVE MARKET
• 10.5 CARDIOVASCULAR DISEASES
  • 10.5.1 INCREASING USE OF MSCS FOR CLINICAL RESEARCH ON IHD TO SUPPORT MARKET GROWTH
• 10.6 OPHTHALMOLOGY
  • 10.6.1 REGENERATION OF EYE TISSUES FOR AMD TO SUPPORT MARKET GROWTH
• 10.7 NEUROLOGY
  • 10.7.1 GROWING NUMBER OF GENE THERAPY PRODUCTS APPROVED FOR NEUROLOGICAL DISEASE TREATMENT TO DRIVE MARKET GROWTH
• 10.8 OTHER THERAPEUTIC AREAS

11 REGENERATIVE MEDICINE MARKET, BY REGION

• 11.1 INTRODUCTION
• 11.2 NORTH AMERICA
  • 11.2.1 US
    • 11.2.1.1 Rising number of pipeline products for regenerative medicine to drive market
  • 11.2.2 CANADA
    • 11.2.2.1 Rising government initiatives for regenerative medicine research to drive market
• 11.3 EUROPE
  • 11.3.1 GERMANY
    • 11.3.1.1 Rising focus on clinical research and patent approvals to drive market
  • 11.3.2 UK
    • 11.3.2.1 Incorporating regenerative medicine into commercial healthcare services under NHS to drive market
  • 11.3.3 FRANCE
    • 11.3.3.1 Structured regulatory framework to drive regenerative medicine product pipeline
  • 11.3.4 ITALY
    • 11.3.4.1 Rising prevalence of neurological and cardiovascular disorders to drive market
  • 11.3.5 SPAIN
    • 11.3.5.1 Favorable regulatory environment to drive product pipeline
  • 11.3.6 REST OF EUROPE
• 11.4 ASIA PACIFIC
  • 11.4.1 CHINA
    • 11.4.1.1 Favorable government support for development of regenerative medicine to drive market
  • 11.4.2 JAPAN
    • 11.4.2.1 Regulatory amendments to pharmaceutical legislation to drive commercialization of therapies
  • 11.4.3 INDIA
    • 11.4.3.1 Introduction of novel therapies for CVD and cancer to support market growth
  • 11.4.4 SOUTH KOREA
    • 11.4.4.1 Strong research base and availability of funds to support market growth
  • 11.4.5 AUSTRALIA
    • 11.4.5.1 Increasing incidence of sports injuries to support market growth
  • 11.4.6 REST OF ASIA PACIFIC
• 11.5 LATIN AMERICA
  • 11.5.1 BRAZIL
    • 11.5.1.1 Gradual increase in pharmaceutical R&D to support market growth
  • 11.5.2 REST OF LATIN AMERICA
• 11.6 MIDDLE EAST
  • 11.6.1 GROWING FOCUS ON GENETIC MEDICINE DEVELOPMENT PROJECTS TO DRIVE MARKET GROWTH IN COMING YEARS
• 11.7 AFRICA
  • 11.7.1 RISING COLLABORATIONS TO SUPPORT MARKET GROWTH IN COMING YEARS

12 COMPETITIVE LANDSCAPE

• 12.1 INTRODUCTION
• 12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
• 12.3 REVENUE ANALYSIS, 2023-2025
• 12.4 MARKET SHARE ANALYSIS, 2025
• 12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025
  • 12.5.1 STARS
  • 12.5.2 EMERGING LEADERS
  • 12.5.3 PERVASIVE PLAYERS
  • 12.5.4 PARTICIPANTS
  • 12.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025
    • 12.5.5.1 Company footprint
  • 12.5.6 REGION FOOTPRINT
  • 12.5.7 PRODUCT FOOTPRINT
  • 12.5.8 THERAPEUTIC AREA FOOTPRINT
• 12.6 COMPANY EVALUATION MATRIX: START-UPS/SMES, 2025
  • 12.6.1 PROGRESSIVE COMPANIES
  • 12.6.2 RESPONSIVE COMPANIES
  • 12.6.3 DYNAMIC COMPANIES
  • 12.6.4 STARTING BLOCKS
  • 12.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025
    • 12.6.5.1 Detailed list of key startups/SMEs
    • 12.6.5.2 Competitive benchmarking of startups/SMEs
• 12.7 COMPANY VALUATION AND FINANCIAL METRICS
  • 12.7.1 VALUATION OF KEY PLAYERS
  • 12.7.2 FINANCIAL METRICS OF KEY PLAYERS (PRODUCTS)
• 12.8 RAND/PRODUCT COMPARATIVE ANALYSIS
• 12.9 COMPETITIVE SCENARIO
  • 12.9.1 PRODUCT LAUNCHES
  • 12.9.2 DEALS
  • 12.9.3 EXPANSIONS

13 COMPANY PROFILES

• 13.1 KEY MARKET PLAYERS
  • 13.1.1 NOVARTIS AG
    • 13.1.1.1 Business overview
    • 13.1.1.2 Products offered
    • 13.1.1.3 Recent developments
      • 13.1.1.3.1 Product approvals
      • 13.1.1.3.2 Deals
      • 13.1.1.3.3 Expansions
    • 13.1.1.4 MnM view
      • 13.1.1.4.1 Key Strengths/Right to win
      • 13.1.1.4.2 Strategic choices made
      • 13.1.1.4.3 Weaknesses & competitive threats
  • 13.1.2 GILEAD SCIENCES, INC.
    • 13.1.2.1 Business overview
    • 13.1.2.2 Products offered
    • 13.1.2.3 Recent developments
      • 13.1.2.3.1 Product approvals
      • 13.1.2.3.2 Deals
    • 13.1.2.4 MnM view
      • 13.1.2.4.1 Key strengths
      • 13.1.2.4.2 Strategic choices
      • 13.1.2.4.3 Weaknesses & competitive threats
  • 13.1.3 SAREPTA THERAPEUTICS, INC.
    • 13.1.3.1 Business overview
    • 13.1.3.2 Products offered
    • 13.1.3.3 Recent developments
      • 13.1.3.3.1 Product launches & approvals
      • 13.1.3.3.2 Deals
    • 13.1.3.4 MnM view
      • 13.1.3.4.1 Key strengths
      • 13.1.3.4.2 Strategic choices
      • 13.1.3.4.3 Weaknesses & competitive threats
  • 13.1.4 AMGEN, INC.
    • 13.1.4.1 Business overview
    • 13.1.4.2 Products offered
    • 13.1.4.3 Recent developments
      • 13.1.4.3.1 Deals
    • 13.1.4.4 MnM view
      • 13.1.4.4.1 Key strengths
      • 13.1.4.4.2 Strategic choices
      • 13.1.4.4.3 Weaknesses & competitive threats
  • 13.1.5 JOHNSON & JOHNSON
    • 13.1.5.1 Business overview
    • 13.1.5.2 Products offered
    • 13.1.5.3 Recent developments
      • 13.1.5.3.1 Product approvals
      • 13.1.5.3.2 Deals
    • 13.1.5.4 MnM view
      • 13.1.5.4.1 Key Strengths/Right to win
      • 13.1.5.4.2 Strategic choices made
      • 13.1.5.4.3 Weaknesses & competitive threats
  • 13.1.6 BIOGEN INC.
    • 13.1.6.1 Business overview
    • 13.1.6.2 Products offered
    • 13.1.6.3 Recent developments
      • 13.1.6.3.1 Product approvals
      • 13.1.6.3.2 Expansions
  • 13.1.7 SMITH+NEPHEW
    • 13.1.7.1 Business overview
    • 13.1.7.2 Products offered
  • 13.1.8 MEDIPOST CO., LTD.
    • 13.1.8.1 Business overview
    • 13.1.8.2 Products offered
    • 13.1.8.3 Recent developments
      • 13.1.8.3.1 Deals
      • 13.1.8.3.2 Other developments
  • 13.1.9 JCR PHARMACEUTICALS CO., LTD.
    • 13.1.9.1 Business overview
    • 13.1.9.2 Products offered
  • 13.1.10 CORESTEM, INC.
    • 13.1.10.1 Business overview
    • 13.1.10.2 Products offered
    • 13.1.10.3 Product pipeline
  • 13.1.11 VERICEL CORPORATION
    • 13.1.11.1 Business overview
    • 13.1.11.2 Products offered
    • 13.1.11.3 Recent developments
      • 13.1.11.3.1 Product approvals
  • 13.1.12 MIMEDX GROUP, INC.
    • 13.1.12.1 Business overview
    • 13.1.12.2 Products offered
    • 13.1.12.3 Recent developments
      • 13.1.12.3.1 Product launches
      • 13.1.12.3.2 Deals
  • 13.1.13 ORGANOGENESIS INC.
    • 13.1.13.1 Business overview
    • 13.1.13.2 Products offered
    • 13.1.13.3 Recent developments
      • 13.1.13.3.1 Deals
  • 13.1.14 MEDTRONIC
    • 13.1.14.1 Business overview
    • 13.1.14.2 Products offered
    • 13.1.14.3 Recent developments
      • 13.1.14.3.1 Deals
  • 13.1.15 BRISTOL-MYERS SQUIBB COMPANY
    • 13.1.15.1 Business overview
    • 13.1.15.2 Products offered
    • 13.1.15.3 Recent developments
      • 13.1.15.3.1 Product approvals
      • 13.1.15.3.2 Deals
  • 13.1.16 AUTOLUS THERAPEUTICS
    • 13.1.16.1 Business overview
    • 13.1.16.2 Products offered
    • 13.1.16.3 Recent developments
      • 13.1.16.3.1 Product approvals
      • 13.1.16.3.2 Deals
• 13.2 OTHER PLAYERS
  • 13.2.1 ORTHOCELL LTD.
  • 13.2.2 MESOBLAST LTD.
  • 13.2.3 BIORESTORATIVE THERAPIES, INC.
  • 13.2.4 PLURISTEM THERAPEUTICS INC.
  • 13.2.5 TEGOSCIENCE
  • 13.2.6 ANTEROGEN. CO., LTD.
  • 13.2.7 BLUEBIRD BIO, INC.
  • 13.2.8 STEMPEUTICS RESEARCH PVT. LTD.
  • 13.2.9 SIBIONO GENETECH CO. LTD.
  • 13.2.10 ASPECT BIOSYSTEMS

14 RESEARCH METHODOLOGY

• 14.1 RESEARCH DATA
  • 14.1.1 SECONDARY DATA
  • 14.1.2 PRIMARY DATA
• 14.2 MARKET SIZE ESTIMATION
  • 14.2.1 PRIMARY INSIGHTS
  • 14.2.2 SEGMENT ASSESSMENT METHODOLOGY: REGENERATIVE MEDICINE MARKET
• 14.3 MARKET BREAKDOWN & DATA TRIANGULATION
• 14.4 STUDY ASSUMPTIONS
• 14.5 RISK ANALYSIS

15 APPENDIX

• 15.1 DISCUSSION GUIDE
• 15.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 15.3 CUSTOMIZATION OPTIONS
• 15.4 RELATED REPORTS
• 15.5 AUTHOR DETAILS

List of Tables

• TABLE 1 REGENERATIVE MEDICINE MARKET: IMPACT ANALYSIS
• TABLE 2 REGENERATIVE MEDICINE MARKET: PORTER'S FIVE FORCES ANALYSIS
• TABLE 3 REGENERATIVE MEDICINE MARKET: ROLE IN ECOSYSTEM
• TABLE 4 AVERAGE SELLING PRICE TREND OF PRODUCTS, BY KEY PLAYER, 2023-2025 (USD)
• TABLE 5 AVERAGE SELLING PRICE OF PRODUCTS, BY REGION, 2025 (USD)
• TABLE 6 REGENERATIVE MEDICINE MARKET: KEY CONFERENCES & EVENTS, 2026-2027
• TABLE 7 REDUCING CAR-T MANUFACTURING TURNAROUND TIME FOR YESCARTA
• TABLE 8 EXPANDING CAR-T MANUFACTURING CAPACITY TO MEET GLOBAL CARVYKTI DEMAND
• TABLE 9 EXPANDING BIOMANUFACTURING CAPACITY FOR REGENERATIVE TISSUE PRODUCTS
• TABLE 10 US-ADJUSTED RECIPROCAL TARIFF RATES
• TABLE 11 INDICATIVE LIST OF PIPELINE PRODUCTS IN PHASE 3, 2025
• TABLE 12 CASE STUDIES OF AI IMPLEMENTATION IN REGENERATIVE MEDICINE MARKET
• TABLE 13 CLIENTS' READINESS TO ADOPT GENERATIVE AI IN REGENERATIVE MEDICINE MARKET
• TABLE 14 LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• TABLE 15 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT (%)
• TABLE 16 KEY BUYING CRITERIA, BY END USER
• TABLE 17 REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
• TABLE 18 REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 19 REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY REGION, 2023-2031 (USD MILLION)
• TABLE 20 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 21 EUROPE: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 22 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 23 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 24 REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 25 REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY REGION, 2023-2031 (USD MILLION)
• TABLE 26 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 27 EUROPE: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 28 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 29 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 30 REGENERATIVE MEDICINE MARKET FOR CELL TRANSPLANTATIONS, BY REGION, 2023-2031 (USD MILLION)
• TABLE 31 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR CELL TRANSPLANTATIONS, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 32 EUROPE: REGENERATIVE MEDICINE MARKET FOR CELL TRANSPLANTATIONS, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 33 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR CELL TRANSPLANTATIONS, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 34 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR CELL TRANSPLANTATIONS, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 35 REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 36 REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY REGION, 2023-2031 (USD MILLION)
• TABLE 37 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 38 EUROPE: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 39 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 40 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 41 REGENERATIVE MEDICINE MARKET FOR AUTOLOGOUS THERAPY, BY REGION, 2023-2031 (USD MILLION)
• TABLE 42 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR AUTOLOGOUS THERAPY, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 43 EUROPE: REGENERATIVE MEDICINE MARKET FOR AUTOLOGOUS THERAPY, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 44 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR AUTOLOGOUS THERAPY, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 45 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR AUTOLOGOUS THERAPY, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 46 REGENERATIVE MEDICINE MARKET FOR ALLOGENEIC THERAPY, BY REGION, 2023-2031 (USD MILLION)
• TABLE 47 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR ALLOGENEIC THERAPY, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 48 EUROPE: REGENERATIVE MEDICINE MARKET FOR ALLOGENEIC THERAPY, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 49 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR ALLOGENEIC THERAPY, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 50 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR ALLOGENEIC THERAPY, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 51 REGENERATIVE MEDICINE MARKET FOR CELL-BASED IMMUNOTHERAPY, BY REGION, 2023-2031 (USD MILLION)
• TABLE 52 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR CELL-BASED IMMUNOTHERAPY, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 53 EUROPE: REGENERATIVE MEDICINE MARKET FOR CELL-BASED IMMUNOTHERAPY, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 54 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR CELL-BASED IMMUNOTHERAPY, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 55 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR CELL-BASED IMMUNOTHERAPY, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 56 APPROVED GENE THERAPIES, 2022
• TABLE 57 REGENERATIVE MEDICINE MARKET FOR GENE THERAPY, BY REGION, 2023-2031 (USD MILLION)
• TABLE 58 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR GENE THERAPY, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 59 EUROPE: REGENERATIVE MEDICINE MARKET FOR GENE THERAPY, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 60 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR GENE THERAPY, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 61 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR GENE THERAPY, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 62 REGENERATIVE MEDICINE MARKET FOR TISSUE ENGINEERING, BY REGION, 2023-2031 (USD MILLION)
• TABLE 63 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR TISSUE ENGINEERING, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 64 EUROPE: REGENERATIVE MEDICINE MARKET FOR TISSUE ENGINEERING, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 65 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR TISSUE ENGINEERING, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 66 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR TISSUE ENGINEERING, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 67 REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2023-2031 (USD MILLION)
• TABLE 68 INDICATIVE LIST OF COMMERCIALIZED REGENERATIVE CELL THERAPIES FOR ONCOLOGY APPLICATIONS
• TABLE 69 REGENERATIVE MEDICINE MARKET FOR ONCOLOGY, BY REGION, 2023-2031 (USD MILLION)
• TABLE 70 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR ONCOLOGY, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 71 EUROPE: REGENERATIVE MEDICINE MARKET FOR ONCOLOGY, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 72 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR ONCOLOGY, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 73 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR ONCOLOGY, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 74 REGENERATIVE MEDICINE MARKET FOR MUSCULOSKELETAL DISORDERS, BY REGION, 2023-2031 (USD MILLION)
• TABLE 75 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 76 EUROPE: REGENERATIVE MEDICINE MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 77 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 78 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 79 INDICATIVE LIST OF REGENERATIVE MEDICINE PRODUCTS COMMERCIALIZED FOR TREATMENT OF ACUTE & CHRONIC WOUNDS
• TABLE 80 REGENERATIVE MEDICINE MARKET FOR DERMATOLOGY & WOUND CARE, BY REGION, 2023-2031 (USD MILLION)
• TABLE 81 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR DERMATOLOGY & WOUND CARE, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 82 EUROPE: REGENERATIVE MEDICINE MARKET FOR DERMATOLOGY & WOUND CARE, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 83 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR DERMATOLOGY & WOUND CARE, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 84 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR DERMATOLOGY & WOUND CARE, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 85 REGENERATIVE MEDICINE MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2023-2031 (USD MILLION)
• TABLE 86 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 87 EUROPE: REGENERATIVE MEDICINE MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 88 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 89 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 90 LIST OF PIPELINE PRODUCTS FOR REGENERATIVE MEDICINE IN OPHTHALMOLOGY
• TABLE 91 REGENERATIVE MEDICINE MARKET FOR OPHTHALMOLOGY, BY REGION, 2023-2031 (USD MILLION)
• TABLE 92 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 93 EUROPE: REGENERATIVE MEDICINE MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 94 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 95 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 96 REGENERATIVE MEDICINE MARKET FOR NEUROLOGY, BY REGION, 2023-2031 (USD MILLION)
• TABLE 97 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR NEUROLOGY, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 98 EUROPE: REGENERATIVE MEDICINE MARKET FOR NEUROLOGY, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 99 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR NEUROLOGY, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 100 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR NEUROLOGY, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 101 REGENERATIVE MEDICINE MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2023-2031 (USD MILLION)
• TABLE 102 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 103 EUROPE: REGENERATIVE MEDICINE MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 104 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 105 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 106 REGENERATIVE MEDICINE MARKET, BY REGION, 2023-2031 (USD MILLION)
• TABLE 107 NORTH AMERICA: REGENERATIVE MEDICINE MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 108 NORTH AMERICA: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
• TABLE 109 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 110 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 111 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 112 NORTH AMERICA: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2023-2031 (USD MILLION)
• TABLE 113 US: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
• TABLE 114 US: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 115 US: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 116 US: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 117 US: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2023-2031 (USD MILLION)
• TABLE 118 CANADA: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
• TABLE 119 CANADA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 120 CANADA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 121 CANADA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 122 CANADA: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2023-2031 (USD MILLION)
• TABLE 123 EUROPE: REGENERATIVE MEDICINE MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 124 EUROPE: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
• TABLE 125 EUROPE: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 126 EUROPE: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 127 EUROPE: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 128 EUROPE: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2023-2031 (USD MILLION)
• TABLE 129 GERMANY: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
• TABLE 130 GERMANY: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 131 GERMANY: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 132 GERMANY: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 133 GERMANY: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2023-2031 (USD MILLION)
• TABLE 134 UK: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
• TABLE 135 UK: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 136 UK: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 137 UK: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 138 UK: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2023-2031 (USD MILLION)
• TABLE 139 FRANCE: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
• TABLE 140 FRANCE: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 141 FRANCE: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 142 FRANCE: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 143 FRANCE: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2023-2031 (USD MILLION)
• TABLE 144 ITALY: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
• TABLE 145 ITALY: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 146 ITALY: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 147 ITALY: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 148 ITALY: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2023-2031 (USD MILLION)
• TABLE 149 SPAIN: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
• TABLE 150 SPAIN: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 151 SPAIN: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 152 SPAIN: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 153 SPAIN: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2023-2031 (USD MILLION)
• TABLE 154 REST OF EUROPE: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
• TABLE 155 REST OF EUROPE: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 156 REST OF EUROPE: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 157 REST OF EUROPE: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 158 REST OF EUROPE: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2023-2031 (USD MILLION)
• TABLE 159 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 160 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
• TABLE 161 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 162 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 163 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 164 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2023-2031 (USD MILLION)
• TABLE 165 CHINA: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
• TABLE 166 CHINA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 167 CHINA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 168 CHINA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 169 CHINA: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2023-2031 (USD MILLION)
• TABLE 170 JAPAN: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
• TABLE 171 JAPAN: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 172 JAPAN: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 173 JAPAN: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 174 JAPAN: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2023-2031 (USD MILLION)
• TABLE 175 INDIA: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
• TABLE 176 INDIA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 177 INDIA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 178 INDIA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 179 INDIA: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2023-2031 (USD MILLION)
• TABLE 180 SOUTH KOREA: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
• TABLE 181 SOUTH KOREA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 182 SOUTH KOREA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 183 SOUTH KOREA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 184 SOUTH KOREA: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2023-2031 (USD MILLION)
• TABLE 185 AUSTRALIA: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
• TABLE 186 AUSTRALIA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 187 AUSTRALIA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 188 AUSTRALIA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 189 AUSTRALIA: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2023-2031 (USD MILLION)
• TABLE 190 REST OF ASIA PACIFIC: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
• TABLE 191 REST OF ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 192 REST OF ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 193 REST OF ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 194 REST OF ASIA PACIFIC: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2023-2031 (USD MILLION)
• TABLE 195 LATIN AMERICA: REGENERATIVE MEDICINE MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 196 LATIN AMERICA: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
• TABLE 197 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 198 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 199 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 200 LATIN AMERICA: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2023-2031 (USD MILLION)
• TABLE 201 BRAZIL: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
• TABLE 202 BRAZIL: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 203 BRAZIL: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 204 BRAZIL: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 205 BRAZIL: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2023-2031 (USD MILLION)
• TABLE 206 REST OF LATIN AMERICA: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
• TABLE 207 REST OF LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 208 REST OF LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 209 REST OF LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 210 REST OF LATIN AMERICA: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2023-2031 (USD MILLION)
• TABLE 211 MIDDLE EAST: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
• TABLE 212 MIDDLE EAST: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 213 MIDDLE EAST: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 214 MIDDLE EAST: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 215 MIDDLE EAST: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2023-2031 (USD MILLION)
• TABLE 216 AFRICA: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
• TABLE 217 AFRICA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 218 AFRICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 219 AFRICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 220 AFRICA: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2023-2031 (USD MILLION)
• TABLE 221 OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN THE REGENERATIVE MEDICINE MARKET
• TABLE 222 REGENERATIVE MEDICINE MARKET: DEGREE OF COMPETITION
• TABLE 223 REGENERATIVE MEDICINE MARKET: REGION FOOTPRINT
• TABLE 224 REGENERATIVE MEDICINE MARKET: PRODUCT FOOTPRINT
• TABLE 225 REGENERATIVE MEDICINE MARKET: THERAPEUTIC AREA FOOTPRINT
• TABLE 226 REGENERATIVE MEDICINE MARKET: DETAILED LIST OF KEY STARTUPS/SMES
• TABLE 227 REGENERATIVE MEDICINE MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES
• TABLE 228 REGENERATIVE MEDICINE MARKET: PRODUCT LAUNCHES, JANUARY 2023-SEPTEMBER 2026
• TABLE 229 REGENERATIVE MEDICINE MARKET: DEALS, JANUARY 2023-SEPTEMBER 2026
• TABLE 230 REGENERATIVE MEDICINE MARKET: EXPANSIONS, JANUARY 2023-SEPTEMBER 2026
• TABLE 231 NOVARTIS AG: COMPANY OVERVIEW
• TABLE 232 NOVARTIS AG: PRODUCTS OFFERED
• TABLE 233 NOVARTIS AG: PRODUCT APPROVALS, JANUARY 2023-SEPTEMBER 2026
• TABLE 234 NOVARTIS AG: DEALS, JANUARY 2023-SEPTEMBER 2026
• TABLE 235 NOVARTIS AG: EXPANSIONS, JANUARY 2023-SEPTEMBER 2026
• TABLE 236 GILEAD SCIENCES, INC.: COMPANY OVERVIEW
• TABLE 237 GILEAD SCIENCES, INC.: PRODUCTS OFFERED
• TABLE 238 GILEAD SCIENCES, INC.: PRODUCT APPROVALS, JANUARY 2023-SEPTEMBER 2026
• TABLE 239 GILEAD SCIENCES, INC.: DEALS, JANUARY 2023-SEPTEMBER 2026
• TABLE 240 SAREPTA THERAPEUTICS, INC.: COMPANY OVERVIEW
• TABLE 241 SAREPTA THERAPEUTICS, INC.: PRODUCTS OFFERED
• TABLE 242 SAREPTA THERAPEUTICS, INC.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023-SEPTEMBER 2026
• TABLE 243 SAREPTA THERAPEUTICS, INC.: DEALS, JANUARY 2023-SEPTEMBER 2026
• TABLE 244 AMGEN, INC.: COMPANY OVERVIEW
• TABLE 245 AMGEN, INC.: PRODUCTS OFFERED
• TABLE 246 AMGEN, INC.: DEALS, JANUARY 2023-SEPTEMBER 2026
• TABLE 247 JOHNSON & JOHNSON: COMPANY OVERVIEW
• TABLE 248 JOHNSON & JOHNSON: PRODUCTS OFFERED
• TABLE 249 JOHNSON & JOHNSON: PRODUCT APPROVALS, JANUARY 2023-SEPTEMBER 2026
• TABLE 250 JOHNSON & JOHNSON: DEALS, JANUARY 2023-SEPTEMBER 2026
• TABLE 251 BIOGEN INC.: COMPANY OVERVIEW
• TABLE 252 BIOGEN INC.: PRODUCTS OFFERED
• TABLE 253 BIOGEN INC.: PRODUCT APPROVALS, JANUARY 2023-SEPTEMBER 2026
• TABLE 254 BIOGEN INC.: EXPANSIONS, JANUARY 2023-SEPTEMBER 2026
• TABLE 255 SMITH+NEPHEW: COMPANY OVERVIEW
• TABLE 256 SMITH+NEPHEW: PRODUCTS OFFERED
• TABLE 257 MEDIPOST CO., LTD.: COMPANY OVERVIEW
• TABLE 258 MEDIPOST: PRODUCTS OFFERED
• TABLE 259 PRODUCT PIPELINE
• TABLE 260 MEDIPOST: DEALS, JANUARY 2023-SEPTEMBER 2026
• TABLE 261 MEDIPOST: OTHER DEVELOPMENTS, JANUARY 2023-SEPTEMBER 2026
• TABLE 262 JCR PHARMACEUTICALS CO., LTD.: COMPANY OVERVIEW
• TABLE 263 JCR PHARMACEUTICALS CO., LTD.: PRODUCTS OFFERED
• TABLE 264 CORESTEM, INC.: COMPANY OVERVIEW
• TABLE 265 CORESTEM, INC.: PRODUCTS OFFERED
• TABLE 266 VERICEL CORPORATION: COMPANY OVERVIEW
• TABLE 267 VERICEL CORPORATION: PRODUCTS OFFERED
• TABLE 268 VERICEL CORPORATION: PRODUCT APPROVALS, JANUARY 2023-SEPTEMBER 2026
• TABLE 269 MIMEDX GROUP, INC.: COMPANY OVERVIEW
• TABLE 270 MIMEDX GROUP, INC.: PRODUCTS OFFERED
• TABLE 271 MIMEDX GROUP, INC.: PRODUCT LAUNCHES, JANUARY 2023-SEPTEMBER 2026
• TABLE 273 ORGANOGENESIS INC.: COMPANY OVERVIEW
• TABLE 274 ORGANOGENESIS INC.: PRODUCTS OFFERED
• TABLE 275 ORGANOGENESIS INC.: PRODUCT LAUNCHES, JANUARY 2023-SEPTEMBER 2026
• TABLE 276 MEDTRONIC: COMPANY OVERVIEW
• TABLE 277 MEDTRONIC: PRODUCTS OFFERED
• TABLE 278 MEDTRONIC: PRODUCT LAUNCHES, JANUARY 2023-SEPTEMBER 2026
• TABLE 279 BRISTOL-MYERS SQUIBB COMPANY: COMPANY OVERVIEW
• TABLE 280 BRISTOL-MYERS SQUIBB COMPANY: PRODUCTS OFFERED
• TABLE 281 BRISTOL-MYERS SQUIBB COMPANY: PRODUCT APPROVALS, JANUARY 2023-SEPTEMBER 2026
• TABLE 282 BRISTOL-MYERS SQUIBB COMPANY: DEALS, JANUARY 2023-SEPTEMBER 2026
• TABLE 283 AUTOLUS THERAPEUTICS: COMPANY OVERVIEW
• TABLE 284 AUTOLUS THERAPEUTICS: PRODUCTS OFFERED
• TABLE 285 AUTOLUS THERAPEUTICS: PRODUCT APPROVALS, JANUARY 2023-SEPTEMBER 2026
• TABLE 286 AUTOLUS THERAPEUTICS: DEALS, JANUARY 2023-SEPTEMBER 2026
• TABLE 287 ORTHOCELL LTD.: COMPANY OVERVIEW
• TABLE 288 MESOBLAST LTD.: COMPANY OVERVIEW
• TABLE 289 BIORESTORATIVE THERAPIES, INC.: COMPANY OVERVIEW
• TABLE 290 PLURISTEM THERAPEUTICS INC.: COMPANY OVERVIEW
• TABLE 291 TEGOSCIENCE: COMPANY OVERVIEW
• TABLE 292 ANTEROGEN. CO., LTD.: COMPANY OVERVIEW
• TABLE 293 BLUEBIRD BIO, INC.: COMPANY OVERVIEW
• TABLE 294 STEMPEUTICS RESEARCH PVT. LTD.: COMPANY OVERVIEW
• TABLE 295 SIBIONO GENETECH CO. LTD.: COMPANY OVERVIEW
• TABLE 296 ASPECT BIOSYSTEMS: COMPANY OVERVIEW
• TABLE 297 ATHERSYS, INC.: COMPANY OVERVIEW

List of Figures

• FIGURE 1 REGENERATIVE MEDICINE MARKET SEGMENTATION & REGIONAL SCOPE
• FIGURE 2 REGENERATIVE MEDICINE MARKET: YEARS CONSIDERED
• FIGURE 3 MARKET SCENARIO
• FIGURE 4 GLOBAL REGENERATIVE MEDICINE MARKET, 2024-2031
• FIGURE 5 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN REGENERATIVE MEDICINE MARKET, 2023-2026
• FIGURE 6 DISRUPTIONS INFLUENCING THE GROWTH OF REGENERATIVE MEDICINE MARKET
• FIGURE 7 HIGH-GROWTH SEGMENTS IN REGENERATIVE MEDICINE MARKET, 2026-2031
• FIGURE 8 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN REGENERATIVE MEDICINE MARKET, IN TERMS OF VALUE, DURING FORECAST PERIOD
• FIGURE 9 GROWING ADOPTION OF CELL & GENE THERAPY TO AID GROWTH
• FIGURE 10 CELL THERAPY SEGMENT ACCOUNTED FOR THE LARGEST MARKET SHARE IN NORTH AMERICA IN 2025
• FIGURE 11 CHINA TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD
• FIGURE 12 CELL THERAPY SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
• FIGURE 13 REGENERATIVE MEDICINE MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
• FIGURE 14 REGENERATIVE MEDICINE MARKET: PORTER'S FIVE FORCES ANALYSIS
• FIGURE 15 REGENERATIVE MEDICINE MARKET: VALUE CHAIN ANALYSIS
• FIGURE 16 REGENERATIVE MEDICINE MARKET: ECOSYSTEM ANALYSIS
• FIGURE 17 REGENERATIVE MEDICINE MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
• FIGURE 18 VC/PRIVATE EQUITY INVESTMENT TRENDS & STARTUP LANDSCAPE
• FIGURE 19 IMPACT OF AI/GEN AI ON REGENERATIVE MEDICINE MARKET
• FIGURE 20 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT
• FIGURE 21 KEY BUYING CRITERIA FOR REGENERATIVE MEDICINE PRODUCTS, BY END USER
• FIGURE 22 NORTH AMERICA: REGENERATIVE MEDICINE MARKET SNAPSHOT
• FIGURE 23 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET SNAPSHOT
• FIGURE 24 REVENUE ANALYSIS OF KEY PLAYERS, 2023-2025 (USD MILLION)
• FIGURE 25 MARKET SHARE ANALYSIS OF KEY PLAYERS, 2025
• FIGURE 26 REGENERATIVE MEDICINE MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025
• FIGURE 27 REGENERATIVE MEDICINE MARKET: COMPANY FOOTPRINT
• FIGURE 28 REGENERATIVE MEDICINE MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025
• FIGURE 29 EV/EBITDA OF KEY PLAYERS
• FIGURE 30 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY PLAYERS
• FIGURE 31 REGENERATIVE MEDICINES PRODUCTS MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS OF REGENERATIVE MEDICINES INSTRUMENTS
• FIGURE 32 NOVARTIS AG: COMPANY SNAPSHOT (2025)
• FIGURE 33 GILEAD SCIENCES, INC.: COMPANY SNAPSHOT (2025)
• FIGURE 34 SAREPTA THERAPEUTICS: COMPANY SNAPSHOT (2025)
• FIGURE 35 AMGEN, INC.: COMPANY SNAPSHOT (2025)
• FIGURE 36 JOHNSON & JOHNSON: COMPANY SNAPSHOT
• FIGURE 37 BIOGEN INC.: COMPANY SNAPSHOT (2025)
• FIGURE 38 SMITH+NEPHEW: COMPANY SNAPSHOT (2025)
• FIGURE 39 MEDIPOST CO., LTD.: COMPANY SNAPSHOT (2023)
• FIGURE 40 JCR PHARMACEUTICALS CO., LTD.: COMPANY SNAPSHOT (2025)
• FIGURE 41 VERICEL CORPORATION: COMPANY SNAPSHOT (2025)
• FIGURE 42 MIMEDX GROUP, INC.: COMPANY SNAPSHOT (2025)
• FIGURE 43 ORGANOGENESIS INC.: COMPANY SNAPSHOT (2025)
• FIGURE 44 MEDTRONIC: COMPANY SNAPSHOT (2025)
• FIGURE 45 BRISTOL-MYERS SQUIBB COMPANY: COMPANY SNAPSHOT (2025)
• FIGURE 46 AUTOLUS THERAPEUTICS COMPANY: COMPANY SNAPSHOT (2025)
• FIGURE 47 RESEARCH DESIGN
• FIGURE 48 BREAKDOWN OF PRIMARIES: REGENERATIVE MEDICINE MARKET
• FIGURE 49 MARKET SIZE ESTIMATION FOR SUPPLY-SIDE ANALYSIS: REGENERATIVE MEDICINE MARKET, 2025
• FIGURE 50 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS, 2025
• FIGURE 51 NOVARTIS AG: REVENUE SHARE ANALYSIS, 2025
• FIGURE 52 PRODUCT-BASED REVENUE ANALYSIS, 2025
• FIGURE 53 VALIDATION FROM PRIMARY EXPERTS
• FIGURE 54 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
• FIGURE 55 CAGR PROJECTIONS: REGENERATIVE MEDICINE MARKET
• FIGURE 56 GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, CHALLENGES, AND OPPORTUNITIES IN REGENERATIVE MEDICINE MARKET
• FIGURE 57 DATA TRIANGULATION METHODOLOGY